Bevacizumab for recurrent ependymoma.

Détails

ID Serval
serval:BIB_EFDAE0A8E452
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Bevacizumab for recurrent ependymoma.
Périodique
Neurology
Auteur(s)
Green R.M., Cloughesy T.F., Stupp R., DeAngelis L.M., Woyshner E.A., Ney D.E., Lassman A.B.
ISSN
1526-632X[electronic]
Statut éditorial
Publié
Date de publication
2009
Volume
73
Numéro
20
Pages
1677-1680
Langue
anglais
Résumé
BACKGROUND: Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed. METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression (TTP), and median overall survival (OS; Kaplan-Meier method). RESULTS: There were 4 men and 4 women with a median age of 40 years (range, 20-65). Prior treatment included surgery (n = 8), RT (8), temozolomide (5), and carboplatin (4). Bevacizumab (5-15 mg/kg every 2-3 weeks) was administered alone (2) or concurrently with cytotoxic chemotherapy including irinotecan (3), carboplatin (2), or temozolomide (1). Six patients achieved a partial response (75%) and 1 remained stable for over 8 months. Median TTP was 6.4 months (95% confidence interval 1.4-7.4) and median OS was 9.4 months (95% confidence interval 7.0-not reached), with a median follow-up of 5.2 months among 5 surviving patients (63%). CONCLUSIONS: The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.
Mots-clé
Phase-Ii, Radiotherapy, Temozolomide, Glioblastoma, Tumors
Pubmed
Web of science
Création de la notice
02/12/2009 16:09
Dernière modification de la notice
03/03/2018 22:35
Données d'usage